Back in 2009, the launch of the first oral therapy for relapsing-remitting multiple sclerosis was much anticipated. Cladribine, initially studied in MS as a parenteral drug in 1994 (Sipe et al. Lancet 1994;244:9-13), had been reformulated as an oral therapy and had completed phase III testing. The new drug, Movectro, earned a fast-track review by the FDA in 2006, and received early approval for use in Russia and Australia. Read More

Ocrelizumab (Ocrevus) has now been approved for use in Canada for the treatment of adults with relapsing-remitting multiple sclerosis  with active disease defined by clinical and imaging features. An application was also submitted for use in primary-progressive MS, but has not yet received approval. The drug was approved by the U.S. Food and Drug Administration earlier this year (see FDA approves ocrelizumab in RRMS, PPMS, NeuroSens, March 30, 2017). Read More

Most MS patients are older at diagnosis, often delay starting treatment, and are likely to remain with the first-choice treatment, according to a survey conducted on MSology, the sister site of NeuroSens. Read More

REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 AAN 2017: There is a growing body of data on the use of disease-modifying therapies in patients with progressive multiple sclerosis. The following is a summary of key studies presented at AAN 2017. Read More